Acute Lymphoblastic Leukemia Therapeutics Market Value Projected to Grow Steadily During 2018-2026



Acute lymphoblastic leukemia (ALL) is a type of cancer affecting the bone marrow and blood. The condition is characterized by overproduction of immature white blood cells, also known as lymphoblast. The immature or abnormal cells are unable to function properly and build up around the healthy cells. Patients diagnosed with ALL are highly susceptible to recurrent infections, anemia, bleeding and bruising easily as the bone marrow is unable to form adequate numbers of red blood cells, white blood cells, and platelets. The cancer is characterized with high progression rate, and can be fatal if not treated within few months. The cancerous cells have the potential to spread to other organs of the body including lymph nodes, liver, spleen, and the central nervous system. The common symptoms of the condition include renal failure, pneumonia, respiratory distress, and bone pain. Acute lymphocytic leukemia is the most common type of cancer in children, where timely treatment and diagnosis results in efficient cure of the condition.


Regional Dynamics


Regional segmentation of the global acute lymphoblastic leukemia therapeutics market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global acute lymphoblastic leukemia therapeutics market over the forecast period, owing to rising prevalence of the disease and rising number of clinical trials undertaken by organizations in the region to address the unmet medical needs of patients. According to the American Cancer Society, 2016, an estimated 5,970 new ALL diagnoses and 1,440 deaths from ALL were registered in 2017. Also, according to the St. Jude Children’s Research Hospital, about 3,000 people aged below 20 years are found to have acute lymphoblastic leukemia each year in the U.S.
Moreover, the St. Jude Children’s Research Hospital, U.S. is focusing on improving outcomes for children with leukemia by undertaking clinical trials to develop novel therapeutics for the condition. For instance, in 2012, the St. Jude Children’s Research Hospital initiated trials for ALLR18 for pediatric relapsed or refractory precursor B-cell acute lymphoblastic leukemia. Moreover, in 2015, Juno Therapeutics, Inc. developed JCAR015 (CD19-targeted CAR T cells), which is currently in the Phase 2 clinical trial, indicated for treating adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).


Competitive Analysis


Manufacturers in the market are focusing on introducing CAR-T cell therapies through strategic collaborations, which is expected to increase the clinical outcomes for ALL. For instance, in 2014, Pfizer, Inc. and Collectis collaborated to develop novel CAR-T immunotherapies. The companies initiated Phase 1 clinical trial for UCART19 in 2016, indicated for pediatric patients with relapsed or refractory B-ALL.
Key players operating in the global acute lymphoblastic leukemia therapeutics market include Novartis Pharmaceuticals, Pfizer Inc., Genzyme Corporation, GlaxoSmithKline Plc., ERYTECH Pharma, Talon Therapeutic, Inc., Sigma-Tau Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc. F. Hoffmann-La Roche Ltd., Biogen Idec, Inc., Bristol-Myers Squibb, and Celgene Corporation.


Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1606


Market Taxonomy


On the basis of drug type, global acute lymphoblastic leukemia therapeutics market is segmented into:
• Chemotherapy Drugs
◦ Nelarabine (Arranon)
◦ Blinatumomab (Blincyto)
◦ Clofarabine (Clolar)
◦ Erwinia (Erwinase)
◦ Pegaspargase (Oncaspar)
◦ Vincristine (Marqibo)
◦ Others
• Immunotherapy Drugs
◦ Tisagenlecleucel (Kymriah)
• Targeted Therapy Drugs
◦ Imatinib (Gleevec)
◦ Dasatinib (Sprycel)
◦ Nilotinib (Tasigna)
◦ Others
• Others


On the basis of indication, global acute lymphoblastic leukemia therapeutics market is segmented into:
• Precursor B Cell ALL
• Mature B Cell ALL
• Precursor T Cell ALL


On the basis of distribution channel, the global acute lymphoblastic leukemia therapeutics market is segmented into:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies


On the basis of region, the global acute lymphoblastic leukemia therapeutics market is segmented into:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa


About Coherent Market Insights


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.




Contact Us


Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Comments

Post a Comment

Popular posts from this blog

Why the Cold Pain Therapy is a Growing Payer Opportunity?

Image
Cold pain therapy is a therapeutic application of cold, used in the treatment of acute soft tissue injuries and to reduce the pain in post-operative condition in orthopedic surgeries, treatment of benign and malignant lesions, and in pain management. Cryotherapy can be applied topically (on the skin surface), surgically or percutaneously. This can also be used to treat various skin conditions such as oral mucositis and tumors in the liver, kidney, bones, breasts and lungs, skin tumors, skin tags, pre-cancerous skin moles, and injuries. Cryosurgery procedure involves use of extreme cold, produced with help of liquid nitrogen (or argon gas) to destroy abnormal tissues. According to the National Cancer Institute (NCI), cryosurgery is used for treatment of several types of cancers and some non-cancerous conditions. It is reported to be effective for treatment in early stage skin cancer, retinoblastoma, actinic keratosis, and cervical intraepithelial neoplasia. Accord...
Read more

Ursodeoxycholic Acid Market Shows Boosted Growth Rate 2018-2026 Estimated by Global Top Players

Image
Ursodeoxycholic acid (UDCA) is a bile acid taken as either a tablet or liquid to treat gallstones and to treat and prevent the progression of cystic fibrosis-related liver disorder. UDCA modifies the bile acid pool by decreasing levels of hydrophobic bile acids while increasing proportion of nontoxic hydrophilic bile acids. UDCA can delay development of gastroesophageal varices and progression to cirrhosis. Moreover it can improve long-term survival in patients with primary biliary cirrhosis. Significant improvement in liver health can be achieved during UDCA therapy in patients with intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, nonalcoholic fatty liver disease, cystic fibrosis-associated liver disease, total parenteral nutrition-induced cholestasis, graft related liver disease, and in some pediatric cholestatic liver diseases. The global ursodeoxycholic acid market size was valued at US$ 346.2 million in 2017, and is expected to witn...
Read more

Booms and Busts in Anatomic Pathology Market; Dynamics Trends Over The Time Discussed 2018-2026

Image
Anatomic pathology involves direct visualization of human tissue as gross examination as well as under a microscope for proper diagnosis of the disease or a pathological condition. Subtypes of anatomic pathology include surgical pathology, oral and maxillofacial pathology, cytopathology, molecular pathology, and forensic pathology. Procedures performed in anatomic pathology include gross examination, histopathology, immunohistochemistry, in situ hybridization, cryopathology, tissue cytogenetics, and others. Standard approach in anatomical pathology is microscopic examination of tissue samples with the help of one or more stains. Manufacturers have developed stains to identify and classify microorganisms in biopsy of tissue samples or excisional specimens. Various gram stains and acid-fast stains have applications in detection of bacteria and mycobacteria in tissue samples. Commercially available products include tissue processing systems, microtomes, cryostats, ...
Read more